ATE401573T1 - Tsg101 als inhibitor der hiv-produktion - Google Patents
Tsg101 als inhibitor der hiv-produktionInfo
- Publication number
- ATE401573T1 ATE401573T1 AT02731876T AT02731876T ATE401573T1 AT E401573 T1 ATE401573 T1 AT E401573T1 AT 02731876 T AT02731876 T AT 02731876T AT 02731876 T AT02731876 T AT 02731876T AT E401573 T1 ATE401573 T1 AT E401573T1
- Authority
- AT
- Austria
- Prior art keywords
- tsg101
- peptides
- hiv
- inhibitor
- hiv production
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29276101P | 2001-05-21 | 2001-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401573T1 true ATE401573T1 (de) | 2008-08-15 |
Family
ID=23126069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02731876T ATE401573T1 (de) | 2001-05-21 | 2002-05-21 | Tsg101 als inhibitor der hiv-produktion |
Country Status (9)
Country | Link |
---|---|
US (2) | US7494767B2 (de) |
EP (1) | EP1401490B1 (de) |
JP (1) | JP2005500825A (de) |
AT (1) | ATE401573T1 (de) |
AU (1) | AU2002303816B2 (de) |
CA (1) | CA2448014A1 (de) |
DE (1) | DE60227665D1 (de) |
IL (1) | IL158981A0 (de) |
WO (1) | WO2002094314A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2236168C (en) * | 1995-11-16 | 2010-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Disruption of expression of multiple alleles of mammalian genes |
US7335468B2 (en) | 2001-03-14 | 2008-02-26 | Myriad Genetics, Inc. | TSG101-GAG interaction and use thereof |
US7202329B2 (en) | 2001-03-14 | 2007-04-10 | Myriad Genetics, Inc. | Tsg101-GAGp6 interaction and use thereof |
AU2002327531A1 (en) | 2001-08-22 | 2003-03-10 | Myriad Genetics, Inc | Therapeutic compositions and methods for treating viral infection |
US7943146B2 (en) | 2001-12-21 | 2011-05-17 | Myrexis, Inc. | Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface |
EP2363205A3 (de) * | 2006-01-11 | 2014-06-04 | Raindance Technologies, Inc. | Mikrofluidische Vorrichtungen Und Verfahren Zur Verwendung Bei Der Bildung Und Kontrolle Von Nanoreaktoren |
CA2668773A1 (en) * | 2006-11-13 | 2008-05-29 | Functional Genetics, Inc. | Therapeutic targeting of escort proteins |
CA2669095A1 (en) * | 2006-11-15 | 2008-05-29 | Functional Genetics, Inc. | Anti-tsg101 antibodies and their uses for treatment of viral infections |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0535021T3 (da) * | 1990-05-21 | 2002-04-15 | Univ Tulane | Association mellem et humant immunodeficiensvirus-beslægtet retrovirus og Sjögren's syndrom |
FR2677654B1 (fr) * | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
US5892016A (en) * | 1997-01-23 | 1999-04-06 | Incyte Pharmaceuticals | Human tumor suppressor |
US5891668A (en) * | 1996-01-16 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian tumor susceptibility genes and their uses |
US5679523A (en) * | 1995-11-16 | 1997-10-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for concurrent disruption of expression of multiple alleles of mammalian genes |
CA2236168C (en) * | 1995-11-16 | 2010-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Disruption of expression of multiple alleles of mammalian genes |
CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US7202329B2 (en) * | 2001-03-14 | 2007-04-10 | Myriad Genetics, Inc. | Tsg101-GAGp6 interaction and use thereof |
-
2002
- 2002-05-21 JP JP2002591030A patent/JP2005500825A/ja active Pending
- 2002-05-21 CA CA002448014A patent/CA2448014A1/en not_active Abandoned
- 2002-05-21 WO PCT/US2002/015965 patent/WO2002094314A1/en active Application Filing
- 2002-05-21 US US10/478,753 patent/US7494767B2/en not_active Expired - Fee Related
- 2002-05-21 IL IL15898102A patent/IL158981A0/xx unknown
- 2002-05-21 DE DE60227665T patent/DE60227665D1/de not_active Expired - Lifetime
- 2002-05-21 EP EP02731876A patent/EP1401490B1/de not_active Expired - Lifetime
- 2002-05-21 AT AT02731876T patent/ATE401573T1/de not_active IP Right Cessation
- 2002-05-21 AU AU2002303816A patent/AU2002303816B2/en not_active Ceased
-
2003
- 2003-09-18 US US10/666,997 patent/US20050009745A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1401490A1 (de) | 2004-03-31 |
US20050009745A1 (en) | 2005-01-13 |
EP1401490A4 (de) | 2005-09-21 |
US20050287525A1 (en) | 2005-12-29 |
JP2005500825A (ja) | 2005-01-13 |
DE60227665D1 (de) | 2008-08-28 |
CA2448014A1 (en) | 2002-11-28 |
WO2002094314A1 (en) | 2002-11-28 |
AU2002303816B2 (en) | 2008-02-14 |
US7494767B2 (en) | 2009-02-24 |
EP1401490B1 (de) | 2008-07-16 |
IL158981A0 (en) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199700221A1 (ru) | Замещенный аминокислотой гидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы | |
DE69715861D1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
EA199700220A1 (ru) | Замещенный бис-аминокислотой гидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы | |
ATE238998T1 (de) | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore | |
EA200400026A1 (ru) | Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза | |
EA199700222A1 (ru) | Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы | |
ATE229033T1 (de) | Heterocyclocarbonyl-aminosäure-hydroxyethylamin - sulfonamid inhibitoren retroviraler proteasen | |
DE59402827D1 (de) | Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv | |
ATE401573T1 (de) | Tsg101 als inhibitor der hiv-produktion | |
DE69414708T2 (de) | Verbindungen und methoden zur inhibition von hiv und verwandten viren | |
RS50831B (sr) | Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid | |
DE60231475D1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
NO970158L (no) | Difluorstaton-antivirale midler | |
WO2006109174A3 (en) | Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid | |
ATE411812T1 (de) | Peptide zur behandlung von infektionen mit dem herpes-virus | |
WO2003052122A3 (en) | Gp41 inhibitor | |
EA202191220A1 (ru) | НОВЫЕ МОЧЕВИНО-6,7-ДИГИДРО-4H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) | |
WO2002064154A3 (en) | Methods and compositions for inhibiting hiv-coreceptor interactions | |
Hutoran et al. | Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease | |
CA2339850A1 (en) | A non-cytolytic recombinant hiv-1 vaccine | |
ATE408421T1 (de) | Pna-konjugat zur therapie von mit hiv in zusammenhang stehenden erkrankungen | |
FI963073A (fi) | Makrosykliset difluorisatonijohdannaiset, jotka ovat käyttökelpoisia viruksia vastustavina aineina | |
MX9706912A (es) | Inhibidores de protesa retroviral de sulfonamida de hidroxietilamino de amino acido y uso de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |